Table 1.
Patient disposition in each brivanib dose cohort and baseline demographics and characteristics
| Brivanib dose cohort | Patients, n |
||
| Part A | Part B | Total | |
| 180 mg | 3 | 0 | 3 |
| 320 mg | 3 | 11 | 14 |
| 600 mg | 3 | 0 | 3 |
| 800 mg continuous | 5 | 15 | 20 |
| 800 mg intermittent | 0 | 11 | 11 |
| 400 mg b.i.d. | 0 | 13 | 13 |
| 1000 mg | 4 | 0 | 4 |
| Demographic | N = 68 | ||
| Age, years | |||
| Median (range) | 61 (29–85) | ||
| Age category, n (%), years | |||
| <65 | 46 (68) | ||
| ≥65 | 22 (32) | ||
| Gender, n (%) | |||
| Male | 38 (56) | ||
| Female | 30 (44) | ||
| Race, n (%) | |||
| White | 63 (93) | ||
| Black | 1 (1) | ||
| Asian | 4 (6) | ||
| ECOG, n (%) | |||
| 0 | 33 (49) | ||
| 1 | 35 (51) | ||
| Tumor type, n (%) | |||
| Colorectal | 44 (65) | ||
| Kidney | 7 (10) | ||
| Hepatocellular carcinoma | 2 (3) | ||
| Other | 15 (22) | ||
| Prior therapy, n (%) | |||
| Prior surgery | 67 (99) | ||
| Prior hormonal, immunologic or biologic therapy | 19 (28) | ||
| Prior radiotherapy | 23 (34) | ||
| Prior chemotherapya | 68 (100) | ||
| No. of regimens | |||
| 1 | 0 (0) | ||
| 2 | 3 (4) | ||
| ≥3 | 65 (96) | ||
a
Included prior systemic anticancer agents.
ECOG, Eastern Cooperative Oncology Group.